This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
Study Type
OBSERVATIONAL
Enrollment
100
No intervention was administered in this study.
Unnamed facility
Glostrup Municipality, Denmark
Unnamed facility
Oslo, Norway
Unnamed facility
Uppsala, Sweden
Time to First Re-treatment
Time to first re-treatment was defined as the time in days between the first administration of Ozurdex® and the following administration of Ozurdex® (re-treatment) in the study eye.
Time frame: 1 Year
Change From Baseline in Best Corrected Visual Acuity (BCVA) Score
BCVA was measured in the study eye using an eye chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity). A positive number improvement in the number of letters read means that the vision improved.
Time frame: Baseline, Weeks 12, 24 and 48
Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT)
Central Retinal Thickness was measured in the study eye using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina to assess retinal thickness. A negative change indicated an improvement.
Time frame: Baseline, Weeks 12, 24 and 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.